Search

The document discusses the issuance of a patent to Kinsa Health LLC for systems and methods for contagious illness surveillance and outbreak detection. The patent aims to leverage user data from a network of temperature sensing probes to identify increased transmission of illness before traditional healthcare systems can detect it. By focusing on underserved populations and utilizing real-time data, the patent seeks to provide early signals of infectious disease outbreaks. The patent outlines a system that can generate illness signals for different population nodes based on user data collected from mobile computing devices. [Extracted from the article]

A patent has been issued for antiviral agents for the treatment of coronaviruses, including SARS-CoV-2, by inventors at Meharry Medical College. The patent addresses the urgent need for effective therapeutics for COVID-19, as there are currently no FDA-approved treatments or vaccines available. The antiviral agent described in the patent utilizes a phosphorodiamidate morpholino oligomer with an antisense sequence to target the replication of coronaviruses in host cells. [Extracted from the article]

A patent application by inventors from various locations was made available online for a method to quantify target nucleic acid loads across multiple samples, particularly for viral nucleic acids like SARS-CoV-2. The method involves amplifying target nucleic acids in test and control samples, generating standard curves, and determining absolute quantities using correction factors. This innovation aims to address challenges in detecting and monitoring pathogenic diseases by enabling comparisons of target nucleic acid loads in samples collected from sources like swabs, excluding blood samples. [Extracted from the article]

A patent has been issued for soluble ACE2 variants developed by inventors at Northwestern University for treating and preventing infections by viruses, particularly coronaviruses like SARS-CoV-2. These variants include fusion proteins and polypeptides that bind to the SARS-CoV-2 spike protein, potentially extending their duration of action. The patent outlines methods for treatment, pharmaceutical compositions, and delivery options, such as pulmonary administration through aerosols or nebulizers. This development could have implications for COVID-19 and other coronavirus infections. [Extracted from the article]

The patent issued for devices and methods for applying therapeutic light to reduce the hazard to healthcare providers of contracting infectious diseases focuses on protecting healthcare providers from exposure to viral infections, particularly during procedures like intubation. The devices and methods aim to reduce or eliminate infectious agents by applying therapeutic light directly to potential sources of infection, such as the mouth and nose of patients. By utilizing therapeutic light, the goal is to decrease the risk of exposure to healthcare providers and improve safety measures in patient care facilities. [Extracted from the article]

A patent has been issued for a mask with self-sealing ports designed to provide access to a patient's nose and mouth while preventing the transmission of harmful particles, viruses, and bacteria. The mask is intended to protect healthcare workers from contaminated air exhaled by patients, particularly in light of the COVID-19 pandemic and the risk of infection. The mask includes features such as endoscope ports and filter passages to enable diagnosis and treatment while maintaining protection for both patients and caregivers. [Extracted from the article]

A patent application for a therapeutic intubation device called the "Therapeutic Endotrachel System" has been submitted by inventor Matthew Corey. The device aims to treat compromised lung tissue, particularly in patients affected by COVID-19, by using ultraviolet-c (UVC) light emitting devices. The patent application outlines the components of the device, including probes, a controller, and specific features related to UVC light emission. This innovative device addresses the need for direct treatment of infected lung tissue, especially in the context of the COVID-19 pandemic. [Extracted from the article]

The patent application "Genetically Engineered Cell-Derived Vaccines" discusses the development of vaccines against infectious diseases, particularly focusing on coronaviruses like SARS-CoV-2. The application highlights the use of genetically engineered cells to express antigens and induce immune responses, aiming to create effective and targeted vaccines with reduced side effects. By utilizing cell-derived vesicles induced from engineered cells, the inventors propose a novel approach to vaccine development that could potentially address the challenges posed by emerging strains of viruses like SARS-CoV-2. [Extracted from the article]

Researchers have submitted a patent application for a method using trigonelline to mitigate cardiomyopathy caused by the SARS-CoV-2 spike protein in obese patients. The application aims to prevent heart injuries by administering trigonelline to attenuate spike-protein exacerbated lipotoxicity and mitochondrial dysfunction in endothelial cells and cardiomyocytes. This method targets post-acute sequelae of COVID-19, particularly in patients with long COVID and heart problems, offering potential therapeutic benefits. [Extracted from the article]

A patent application titled "Method And System For Measuring Cell-Mediated Immunity To Adeno-Associated-Virus Infection" was published online by inventors Ashokkumar and Sindhi. The application discusses the importance of measuring cell-mediated immunity in gene therapy using adeno-associated viruses (AAV) as vehicles. The method involves mixing white blood cells with viral antigens and measuring immune responses to assess the risk of immune reactions. This technology aims to enhance the management of immunosuppression after gene therapy and improve patient outcomes. [Extracted from the article]

A patent application by inventors from Reykjavik, Iceland, describes an antimicrobial formulation containing free fatty acids (FFA) to inhibit microbial growth, particularly for treating viral respiratory infections like coronavirus. The FFA extract in the formulation is effective at concentrations ranging from 0.1% to 20% and can reduce microbial replication by up to 99.99%. The formulation can be administered orally, nasally, ocularly, or topically to prevent and treat infections caused by various viruses, including coronaviruses. [Extracted from the article]

A recent study conducted by investigators from McGill University in Montreal, Canada, focused on the necessity of virtual education for the global gastroenterology community in light of the COVID-19 pandemic. The study surveyed leaders of the World Gastroenterology Organization (WGO) to assess the need for a virtual global gastroenterology educational program, with a majority of respondents highlighting clinical gastroenterology and endoscopy as key educational topics. The research emphasized the importance of leveraging virtual platforms for communication and dissemination of knowledge in the field of gastroenterology. [Extracted from the article]

A report from Ohio State University discusses the establishment of the Ohio Coronavirus Wastewater Monitoring Network (OCWMN) to monitor SARS-CoV-2 levels in wastewater across the state. The network, initiated in response to the COVID-19 pandemic, monitors over 70 locations twice a week and provides publicly available data on a weekly basis. The research aims to inform future pandemic responses and wastewater monitoring efforts, providing a valuable tool for public health professionals. [Extracted from the article]

A recent study conducted at the University of Faisalabad in Pakistan focused on the synthesis, characterization, and biological evaluation of a new compound called 4-(4-(2hydroxyethyl)phenylamino)-4-oxobutanoic acid (HPO) and its organotin(IV) complex (SnHPO). The research utilized various analytical techniques to investigate the molecular structures and properties of these compounds, including their potential antimicrobial activities and interactions with the SARS-CoV-2 virus receptor protein. The findings suggest that both HPO and SnHPO exhibit strong antimicrobial properties and may have potential as therapeutic drugs for various microbes. [Extracted from the article]

Researchers at Zhejiang University of Technology conducted a study on the effects of sodium hypochlorite (NaClO) on lipid metabolism in larval zebrafish. The study found that exposure to NaClO disrupted lipid metabolism and gene transcription in the zebrafish, with over 700 differentially expressed genes identified. The research provides new insights into the toxicological effects of chlorine-containing disinfectants on aquatic organisms. This study was funded by various organizations in China and published in the journal Toxics. [Extracted from the article]

Researchers at Dankook University have developed the KODARI application, an epidemiological investigation support system for managing infectious diseases like coronavirus. The application allows users to voluntarily participate in epidemiological investigations and transmit self-management information in real-time. Through user evaluations, it was found that the application improved data accuracy, shortened the time required for investigations, and received high ratings from users. This model of voluntary participation shows promise in enhancing epidemiological investigations and reducing the duration of the process. [Extracted from the article]

A patent has been issued for biometrically-linked electronic proof of an individual's health status, particularly in response to the COVID-19 pandemic. The patent, filed by inventors from various locations in the United States, aims to provide a secure and privacy-respecting method for individuals to prove their health status without revealing sensitive personal information. This technology could potentially facilitate economic and social reintegration, reduce the need for invasive monitoring, and enable individuals to return to work, travel, and care for vulnerable populations with fewer restrictions. The patent, assigned to Mastercard International Incorporated, outlines a system that involves capturing biometrics, generating a biometric token, and linking health status information to provide electronic proof of health status. [Extracted from the article]

A patent application titled "Ribonucleoprotein Nanocomplex Vaccines And Uses Thereof" was published online by inventors from Hong Kong, focusing on a vaccine composition comprising nano-complexes with viral RNA and adaptor-antigen polypeptides. The invention aims to provide a safe and effective vaccine that can be administered intranasally or orally to prime tissue-resident immune cells against viral targets without causing adverse side effects. The vaccine composition offers heterosubtypic protection against multiple virus subtypes and species, including SARS-CoV-2, influenza, respiratory syncytial virus, and hepatitis C virus. [Extracted from the article]

Researchers Drummer and Poumbourios have submitted a patent application for a vaccine antigen that aims to improve immune responses to coronaviruses, particularly variants of concern. The antigen is designed to elicit neutralizing antibody responses and enhance stability and immunogenicity. The patent application outlines various aspects of the vaccine antigen, including modifications to the S protein trimer, vector encoding, and methods of production and administration. This development addresses the need for effective antigens to combat evolving viral variants and prevent coronavirus infections. [Extracted from the article]

A patent application by Kevin G. Rice discusses the development of double-stranded mRNA vaccines, which are more stable than single-stranded mRNA vaccines. These vaccines aim to provide enhanced stability and effectiveness in preventing, inhibiting, or treating various diseases, including viral infections like SARS-CoV-2, cancer, and other vaccine-treatable diseases. The patent application details the composition, method of administration, and potential applications of these double-stranded mRNA vaccines, highlighting their potential in targeted gene delivery systems and immune response enhancement. [Extracted from the article]

A patent application titled "Mask-Based Diagnostic Utilizing Ai Algorithms For Improved Patient Outcomes" by inventor John J. Daniels focuses on developing a diagnostic system using digital and analog devices to detect biomarkers of various diseases, including COVID-19 and cardiovascular conditions, from bodily fluids like exhaled breath. The system utilizes mask-based diagnostic (MBD) technology to collect and analyze biomarker data, incorporating artificial intelligence (AI) algorithms for pattern recognition and feedback to enhance patient outcomes. This innovative approach aims to enable remote monitoring of patients with cardiovascular disease and improve early detection and intervention strategies. [Extracted from the article]

A patent application titled "Ofatumumab For Treating Pediatric Ms" was published online, highlighting the high burden of pediatric multiple sclerosis (MS) on patients and their families. Current treatment options for pediatric MS are limited, leading to a significant unmet medical need. Ofatumumab, a monoclonal antibody targeting CD20, has shown promise in treating MS in adults and is now being explored for pediatric MS patients, offering potential benefits for this vulnerable population. The patent application outlines the potential use of ofatumumab in treating or preventing MS in pediatric patients with specific weight and age criteria, presenting a novel approach to addressing the challenges faced by this patient group. [Extracted from the article]

The patent application by John J. Daniels introduces a mask-based diagnostic system that utilizes AI algorithms to detect biomarkers of various diseases, including COVID-19 and cardiovascular conditions, from exhaled breath samples. The system aims to improve patient outcomes by enabling remote monitoring and early detection of physiological conditions through the analysis of biomarkers and biometric data. By collecting and analyzing data using machine learning algorithms and biosensors integrated into face masks, the system provides personalized alerts for healthcare interventions based on predicted likelihood of future cardiac events. [Extracted from the article]

Researchers have submitted a patent application for a "Gas Purification Apparatus For Nasal Application" designed to remove contaminants and impurities from the air before inhalation. The apparatus includes a filtration component, a nose plug component, and a cap to deliver purified air to the nasal cavity. The device aims to reduce exposure to harmful airborne viruses like COVID-19 and improve respiratory health. [Extracted from the article]

A patent application by inventor Sajish Mathew discusses the neuroprotective effects of cis-resveratrol, a natural compound, in treating neurodegenerative diseases like Alzheimer's and Parkinson's, as well as metabolic conditions such as diabetes and obesity. The application highlights the potential benefits of cis-resveratrol at lower doses, contrasting with the detrimental effects observed at higher doses. The document emphasizes the importance of isomer-specific dosing to maximize therapeutic outcomes and minimize adverse effects in various health conditions. [Extracted from the article]

A patent has been issued for a system and method for managing shared vehicles, particularly in response to the COVID-19 pandemic. The system aims to remotely determine the health condition of passengers in order to ensure the safety of subsequent passengers. It involves detecting respiratory disease symptoms, assessing ventilation status, generating infection risk information, and transmitting this information to relevant parties to improve safety measures. The patent emphasizes the importance of hygiene and safety in shared vehicle services during the pandemic. [Extracted from the article]

A patent has been issued for an infection risk mapping device, method, and computer-readable storage medium by Fujifilm Corporation. The invention aims to prevent the spread of infectious diseases, particularly focusing on asymptomatic carriers and individuals in the incubation period of COVID-19. The device acquires position and vital information of users to determine infection risk, specify risk places, and distinguish between asymptomatic carriers and confirmed infected individuals. The technology provides a novel approach to mapping infection risk and offers recommendations for monitoring, testing, and cleaning to prevent disease spread. [Extracted from the article]

A patent application by Julian Henley from New Orleans, LA, US, proposes electro-ionic devices for enhanced protection against airborne biopathogens, including COVID-19. The devices aim to address the challenges of viral transmission through small airborne particles that can bypass the body's defense mechanisms. The invention involves applying different voltages and generating ozone to improve filtration and kill viral particles in real-time. The patent application outlines various embodiments of the electro-ionic devices, emphasizing their potential to enhance respiratory protection. [Extracted from the article]

Researchers have submitted a patent application for a "Fluid Cleaning Circulator" designed to deactivate harmful microorganisms in fluids using ultraviolet light irradiation. The invention aims to address issues such as high electric power consumption, inefficiency in ultraviolet light irradiation, and low reflection efficiency. By utilizing an ultraviolet light LED element and surface processing that reflects ultraviolet light, the circulator maximizes the utilization of irradiated ultraviolet light and prevents leakage of harmful ultraviolet light. The patent application was filed on September 5, 2022, and made available online on October 17, 2024. [Extracted from the article]

The patent application discussed in the article focuses on methods, devices, and kits for detecting the presence of the SARS-CoV-2 virus in samples from subjects. The application details the use of antibodies and antigen-binding fragments to detect specific proteins from the virus, particularly the nucleocapsid (N) protein. The inventors aim to provide tools for assessing coronavirus transmission in humans, emphasizing the need for accurate detection methods due to the health risks associated with SARS-CoV-2. [Extracted from the article]

A patent application titled "Methods Of Diagnosing, Prognosing, And Treating Multisystem Inflammatory Syndrome In Children (Mis-C) And Severe Covid-19, And Apparatuses Thereof" was published online on October 17, 2024, by inventors Gennaro, Maria L.; Guzman Rivera, Jeisac; Moore, Dirk Foster. The application focuses on detecting biomarkers associated with MIS-C and severe acute COVID-19 in pediatric populations to enable early diagnosis and proper treatment. The patent application outlines methods, uses, and apparatuses for diagnosing, prognosing, and treating MIS-C and severe acute COVID-19, emphasizing the importance of sensitive assays for early detection. [Extracted from the article]

The article discusses the global hydrogen electrolyzer market, projecting a growth to US$497.07 million by 2028 with a CAGR of 6.57% from 2024-2028. Factors driving market growth include increasing global carbon emissions, production of low-carbon hydrogen, ammonia, margarine, menthol, and semiconductors. Challenges include lack of hydrogen storage facilities and health effects. The market is segmented by region, with North America leading in 2023, but facing slowdown due to COVID-19 impacts. Major players in the market include Siemens AG, ITM Power, NEL ASA, FuelCell Energy, Air Liquide, and Plug Power. [Extracted from the article]

The patent application by Bharat Biotech International Limited discusses a method for generating a robust immune response against COVID-19 through a combination of parenteral and mucosal immunization. The approach aims to address the limitations of existing COVID-19 vaccines by enhancing mucosal immunity to prevent viral transmission. By administering vaccines through different routes and utilizing various adjuvant formulations, this method seeks to provide broader protection against SARS-CoV-2 infection. The invention highlights the importance of heterologous vaccination strategies in developing effective responses to the evolving COVID-19 pandemic. [Extracted from the article]